Date: 2014-10-20
Type of information: Nomination
Compound:
Company: Cubist Pharmaceuticals (USA - MA)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On October 20, 2014, Cubist Pharmaceuticals announced that its Board of Directors has selected Robert J. Perez as the Company’s Chief Executive Officer, effective January 1, 2015. Perez, who currently serves as Cubist’s President and Chief Operating Officer, will succeed Michael W. Bonney who is retiring from his current role as CEO on December 31, 2014, and will become non-executive Chair of Cubist’s Board of Directors. Current Board Chair, Kenneth M. Bate, will become Lead Independent Director. Mr. Perez has served in various senior positions at Cubist for 11 years. He was appointed COO in 2007, President in 2012 and has been a member of the Board since April 2014. Prior to joining Cubist, Mr. Perez served as Vice President of Biogen, Inc.\'s CNS Business Unit where he was responsible for leading the U.S. neurology franchise. From 1995 to 2001 he served as a Regional Director, Director of Sales, and Avonex® Commercial Executive at Biogen. From 1987 to 1995, Mr. Perez held various sales and marketing positions at Zeneca Pharmaceuticals. Mr. Perez is a Director at AMAG Pharmaceuticals, Inc. and from 2006 - 2009 served as a Director at EPIX Pharmaceuticals, Inc. He is also a Trustee of the Dana-Farber Cancer Institute and a Director of the California Healthcare Institute, the Biomedical Science Careers Program, and a member of the Board of Advisors of Citizen Schools of Massachusetts.
Financial terms:
Latest news:
